Sean Elyan
Cheltenham General Hospital
9 Papers
142 Citations
Sean Elyan is an academic researcher from Cheltenham General Hospital. The author has contributed to research in topics: Radiation therapy & Medicine. The author has an hindex of 7, co-authored 9 publications.
Chat about Author
Papers
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.
Russell D. Petty,Asa Dahle-Smith,David A J Stevenson,Aileen Osborne,Doreen Massie,Caroline Clark,Graeme I. Murray,Susan J Dutton,Corran Roberts,Irene Chong,Wasat Mansoor,Joyce Thompson,Mark Harrison,Anirban Chatterjee,Stephen Falk,Sean Elyan,Angel Garcia-Alonso,David Walter Fyfe,Jonathan Wadsley,Ian Chau,David Ferry,Zosia Miedzybrodzka +21 more
TL;DR: EGFR CNG assessed by FISH appears to identify a subgroup of patients with esophageal cancer who may benefit from gefitinib as a second-line treatment, and anti-EGFR therapies should be investigated in prospective clinical trials in different settings in EGFR FISH-positive and, in particular, EGFR-amplified esophagal cancer.
The management of histologically unverified presumed cerebral gliomas with radiotherapy
TL;DR: Patients diagnosed on the basis of clinical features and imaging as having presumed glioma have similar natural history and clinical behavior after treatment with radiotherapy to those with histologically confirmed gliomas, but the results should not be taken as justification for avoiding biopsy.
86
Radiation pneumonitis following treatment of non-small-cell lung cancer with continuous hyperfractionated accelerated radiotherapy (CHART).
TL;DR: Univariate analysis revealed that the percentage lung volume receiving more than 20 Gy (V20) and the mean lung dose are of predictive value for the development of pneumonitis after CHART, and CHART appears to have a superior therapeutic index than conventionally fractionated radiotherapy.
61
Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer.
TL;DR: Overall obese patients are in fact less likely to suffer haematological toxicity and drug doses need not be reduced on the basis of obesity.
35
Improving the acceptability of high-dose radiotherapy by reducing the duration of treatment: accelerated radiotherapy in high-grade glioma
Michael Brada,G Thomas,Sean Elyan,N. James,F Hines,Stanley W. Ashley,H. Marsh,BA Bell,S Stenning +8 more
TL;DR: The effectiveness and convenience of a short accelerated regimen makes this a suitable alternative to a 6 week course of radiotherapy in patients with high-grade glioma, however, a full randomised trial comparing conventional and accelerated radiotherapy may be required as proof of equivalence.
26